Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What a joke . etrade sucks!
yep yahoo is my back up eom
ALMI 10Q out >>>>>>>>>
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001144204%2D03%2D006999%2Etxt&FilePath...
to tired to read. have fun.
PWRC - ahhhhhhh thats why, thanks BB. Float 6M, o/s 11M. Nice find Vlisxpert.
PRG bid building. Seems seeling is over. eom
PRG - in. Along with AAC & CNV & NVI, got IPT this morning too. Portfolio full of AMEX beauties.
Buzz, any opinion on IPT. Liked their numbers today, pretty cheap co.
Thanks & Good luck!
OT great reply EYE.
[edit] deleted text body.
Omni, you were so right. I have that stupid rule: No chasing. My trading was mixed today, so I didnt feel like chasing a low floater. One thing is for sure: U DA MAN!!!
Maybe I get an opp on a hard shake.
FNIX in on PR, could run again. >>>
Fonix Partners With a-technic to Provide DECtalk Text-to-Speech Technology to Disabled Technology Users
Tuesday November 11, 12:15 pm ET
SALT LAKE CITY--(BUSINESS WIRE)--Nov. 11, 2003--Fonix® Corp. (OTC BB: FNIX), an international provider of leading speech interface solutions, announces a cooperative technology partnership with a-technic, a nonprofit research and development charity, to promote Fonix DECtalk(TM) text-to-speech (TTS) as a speech technology solution to clients and partners.
a-technic researches and develops products for blind, low-vision and disabled technology users, then makes that technology available to other organizations to market and sell end-user products. By incorporating DECtalk into their easy-to-use computer platform, a-technic offers their manufacturing partners the most intelligible TTS voices available.
Fonix DECtalk is the premier TTS solution in today's speech industry due to its high intelligibility, low memory footprint, nine voices (four male, four female, one child) and multiple languages (U.S. and U.K. English, European French, German, Castilian and Latin American Spanish).
"a-technic needs a compact, intelligible, flexible and stable TTS solution for development of our low-cost, easy-to-use talking computer appliances for blind users," said John Batty, a-technic CTO. "Fonix DECtalk is clearly the best product on the market for meeting these requirements."
"This partnership is a great opportunity for both Fonix and a-technic," said John Oelfke, vice president of Fonix Embedded Speech Solutions. "Working together, we can offer the best speech-based interface technology currently available to the assistive market. Our mutual goal is to make it easier and more convenient for visually impaired, blind or disabled people to access computers and devices." As a-technic's products are made available to their manufacturing partners for deployment to the user community, Fonix will receive royalty revenue from these sales.
About a-technic
a-technic is a U.K.-registered charity specializing in technology to help people with disabilities.
Their mission is to research, develop and promote adaptive and assistive technologies that help people with physical disabilities cope with day-to-day living. Visit www.a-technic.net for more information.
About Fonix
Fonix Corp. provides speech interface solutions for mobile/wireless devices, computer telephony systems, vehicle telematics, the assistive market and embedded devices. Manufacturers and developers incorporate Fonix technology to provide their customers with an easy, convenient, reliable user experience. Visit www.fonix.com for an introduction to Fonix's complete suite of speech solutions.
Investor contact:
ECON Corporate Services
www.investorideas.com
866-894-3913
The statements released by Fonix Corp. that are not purely historical are forward looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions and strategies for the future. Forward-looking statements involve risk and uncertainties that may affect the company's business prospects and performance. The company's actual results could differ materially from those in such forward-looking statements. Risk factors include general economic, competitive, governmental and technological factors as discussed in the company's filings with the SEC on Forms 10-K, 10-Q and 8-K. The company does not undertake any responsibility to update the forward-looking statements contained in this release.
--------------------------------------------------------------------------------
Contact:
Fonix Corp., Salt Lake City
Elizabeth Sweeten, 801-553-6600
mediainfo@fonix.com
--------------------------------------------------------------------------------
Source: Fonix Corp.
PFCE no chance to fill. Passing.
ADZR - Nite backed off ask wall .30 to .32 ..... good, holding it along with WVNTF.
WVNTF holding it tight here. Very stong - Thanks OMNI. Holding ADZR partially too, watching if breaks .30 wall, Out PRVH at open (pure gap play for me).
I had fun! eom
MDPA >>> here is the report:
METCARE Announces Third Quarter Results
Monday November 10, 2:07 pm ET
Reports Third Quarter Net Income of $1.2 Million
http://biz.yahoo.com/bw/031110/105787_1.html
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 10, 2003--Metropolitan Health Networks, Inc. (METCARE(SM)) (OTCBB:MDPA - News), a leading provider of healthcare services, today announced results for the three months ended September 30, 2003. The Company reported net income of $1.2 million on revenues of $35.7 million, compared to a net loss of $2.0 million and revenues of $34.6 million in the prior year quarter. On a basic per share basis, net income was $.03, compared to a loss of $.06 for the third quarter of 2002.
For the nine months ended September 30, 2003, the Company reported net income of $2.8 million on revenues of $108.4 million, compared to a net loss of $3.6 million and revenues of $105.2 million in the prior year period. On a basic per share basis, net income was $.08, compared to a loss of $.12 for the first nine months of 2002.
Income from continuing operations was nearly $1.7 million and $4.3 million for the three months and nine months ended September 30, 2003, respectively, compared to losses in the prior year periods. The 2003 results include losses from discontinued operations of $519,000 and $1.5 million for the third quarter and first nine months, respectively, compared to losses of $1.7 million and $2.4 million in the prior year periods. These losses reflect the operations of the Company's pharmacy division in 2003, and both the pharmacy and clinical laboratory in 2002.
With regard to the previously announced agreement to sell its Metcare Rx pharmacy unit, the Company reported that the parties to the transaction are working to complete the transaction. While there can be no assurance that the sale will be finalized, management believes that the completion of the deal is near.
Mike Earley, President and CEO, commented, "We continue to be pleased with our 2003 results. Not only have we maintained our profitability from the first two quarters, but also have continued to improve on a cash flow-basis, with related improvements in both working capital and net worth. These results have allowed us to make positive strides in addressing our various balance sheet issues, and in fact, we have reduced our total liabilities by more than $3 million during the first nine months of the year."
About Metropolitan Health Networks, Inc.
METCARE is a growing healthcare organization in Florida. The Company currently manages healthcare services for patients in South and Central Florida and is part of a network of physicians serving more than a million people from Miami to Daytona Beach on Florida's East Coast.
To learn more about Metropolitan Health Networks, Inc., please visit its website at http://www.metcare.com
Certain statements contained in this news release, which are not based on historical facts, are forward-looking statements as the term is defined in the Private Securities Litigation Reform Act of 1995, and are subject to uncertainties and risks in part detailed in the company's Securities and Exchange Commission 10-K, 10-Q, S-8 and 8-K filings, that may cause actual results to materially differ from projections. Although Metropolitan Health Networks, Inc. believes its expectations are reasonable assumptions within the bounds of its knowledge of its businesses and operations; there can be no assurance that actual results will not differ materially from their expectations. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include the company's ability to continue as a going concern; volatility of the company's stock and price; the ability to raise funds for working capital and acquisitions; access to borrowed or equity capital on favorable terms. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this report will, in fact, occur.
--------------------------------------------------------------------------------
Contact:
Metropolitan Health Networks, Inc., West Palm Beach
Michael M. Earley or David S. Gartner, 561/805-8500
--------------------------------------------------------------------------------
Source: Metropolitan Health Networks, Inc.
MDPA - in ... late, but heavy. Great PR. eom
Ez/WVNTF... now we only need NITE to back off....... :)
GL & thanks omni
WVNTF - in with omni.... looking good. NITE backed off .30 very quickly. GL
Vlis, that is interesting. I thought ofthat myself: Buying all popular subs atbottom for small amounts of capital, and just letting them sit until they run again. Thanksfor the calls on ADVC and THTHF. GL
THTHF - in at .0023
THTHF - Vlis you are hot subber lately. In with you. GL
ADZR - very nice, in at .26. Thanks Omni
You wrote a book? Out yet? eom
ADVR comeback... where is next resistance.... .15?
World cup,
Paper trading is good. I preferred to lose 50% of my holding first, but the good thing is I learned some things I will never ever forget.
Some good books by authors
John Murphy
Alexander Elder (Trading for a living)
Edwards & Magee (Technical Analysis....)
All in there, check stockcharts.com also (Click Chartschool)
GL to you!
RTEKE - in on EZ´s call, had to chase it. Nite never filled on ask.
ADVR in on news and break of .10 >>>
ADVR Reports Positive Preliminary Results of AVR118 Clinical Trial in AIDS Patients Suffering from Body Wasting (Cachexia)
Monday November 10, 8:21 am ET
Patients Show Improved Appetite, Weight Stability or Gains, and Enhanced Quality of Life
YONKERS, N.Y., Nov. 10 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - News) today reported that preliminary results from the first 15 cachectic (wasting) AIDS patients treated with the Company's novel immunomodulator AVR118 showed improvement in appetite, weight gain or stability, and enhanced quality of life in all the patients. None of the 15 patients reported any significant side effects from AVR118 (formerly known as Product R) therapy. Cachexia is a state of body malnutrition and wasting with loss of body fat and lean body weight.
ADVERTISEMENT
The 15 patients who completed the trial included eight males, five on highly active antiretroviral therapy (HAART), and seven females, five of whom were receiving HAART. The primary indication of the trial is the treatment of cachexia (body wasting). The patients are part of a Phase I/Phase II open- label dose escalation clinical trial being conducted at The Kaplan Medical Center in Rehovot, Israel.
"We have taken the unusual step of publicizing these preliminary results, despite the small population of patients, because of the apparent strong clinical results demonstrated, even in this short course treatment protocol, by AVR118 in these very ill patients," said Eli Wilner, Chairman of the Board of ADVR. "If the continuation of the study confirms these preliminary findings, the value of AVR118 in treating body wasting in AIDS patients will merit much broader scientific analysis in a large study of AIDS patients."
"These preliminary results are very encouraging because a positive clinical effect was seen in virtually all patients following initiation of treatment with AVR118, even at the lowest dosage," said James D'Olimpio, M.D., Director of the North Shore University Hospital's Supportive Oncology and Palliative Care Service, and a member of ADVR's Scientific Advisory Board. "The study design and quality of data is worthy of a presentation at an appropriate international scientific meeting. I would encourage the investigators to prepare an abstract once the statistical analysis of the data set is completed so that these promising preliminary results can be shared with the global scientific community." Dr. D'Olimpio has done extensive research on cachexia, particularly in cancer patients.
When completed, the clinical trial will include a total of 30 patients, with 10 each receiving AVR118 administered subcutaneously per day at the three doses of 0.4 ml, 2 ml, and 4 ml. The trial protocol specifies a two-week preliminary observation period followed by four weeks of AVR118 therapy and four weeks of observation.
"The preliminary results demonstrate the potential utility of AVR118 in this group of patients," said Richard A. Guarino, M.D., ADVR's clinical and regulatory advisor.
"These preliminary results in cachectic AIDS patients are encouraging, and I eagerly await possible confirmation of our preliminary results once all 30 patients have completed the trial," said Shalom Z. Hirschman, M.D., ADVR's Chief Scientist. "These results garnered midway through the clinical trial appear to validate our expectations of the clinical activity of the unique immunomodulator AVR118."
ADVR's AVR118 represents a biopolymer chemistry that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. Therefore, AVR118 has been termed a "switch-type" immunomodulator. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS.
For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com.
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
http://biz.yahoo.com/prnews/031110/nym128_1.html
Yes, snatched some in pre. Very nice. Buzz, I sent you an email to your yahoo adress. Got it?
DKEY - wow, nice premarket play the rumor eom
DKEY in premarket...... looks like breaking the .70/.90 channel, no news, just rumors..... Ran hard last time. Was very strong last Friday in a/h. Maybe interesting play for a dollar+ run?
DKEY - channel break in premarket: Broke the .70-.90 channel which lasted 4 weeks. Very heavy volume in Friday A/H, looks nice this a.m.
Skatchmo - Stockcharts paid services do not include more OTC stocks than the free site (but more helpfull tools). Use Bigcharts.com for those that are not at Stockcharts.com and for Pink Sheet stocks. Bigcharts are worse in terms of quality, but better than "flying blind".
It was Patsy´s. eom
OMNI - what book is that. Missed the show.
Thanks for the great post on the opening bell!
Spockster - TRAC interesting. Had in on watch for a long time an traded th channel once. Was very quiet lately, but seems to be on a breakout, and the financials shouldnt be too bad in a bull market like this.
http://stockcharts.com/def/servlet/SC.web?c=trac,uu[w,a]daclyyay[dc][pb50!d20,2!f][vc60][iUb14!La12,...
Earnings out Tuesday.
Back on my Radar.
Thanks
WIN - speaking of double bottoms..... whats your take?
http://stockcharts.com/def/servlet/SC.web?c=WIN,uu[w,a]daclyyay[dc][pb50!b200!f][vc60][iUb14!La12,26...
TIA
excellent! eom
Yeah I prefer 1998 -means 1999 and early 2000 still to come LOL
CSOL/IlikeBB - yep, should pop imo- looking at the chart, it ran hard last time it had volume.
Lisp - in THTHF with you. looks like a bottom. thanks, hope that Pig will fly.
GL
Oops, not a breakout as defined here -sorryeom